Clinical Trial Details
— Status: Terminated
Administrative data
| NCT number |
NCT00962286 |
| Other study ID # |
OBEFUR |
| Secondary ID |
|
| Status |
Terminated |
| Phase |
N/A
|
| First received |
August 18, 2009 |
| Last updated |
August 3, 2011 |
| Start date |
September 2009 |
| Est. completion date |
July 2010 |
Study information
| Verified date |
August 2009 |
| Source |
Rabin Medical Center |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
Israel: Ethics Commission |
| Study type |
Interventional
|
Clinical Trial Summary
Background: Obesity is associated with a high prevalence of chronic kidney disease. The
glomerular hyperfiltration associated with obesity may play a role in the pathogenesis of
obesity associated chronic kidney disease. Attenuation of hyperfiltration by pharmacological
means may slow down the development and progression of chronic renal failure. The
investigators have previously shown that acetazolamide, a proximally acting diuretic that
activates TGF by increasing solute delivery to the macula densa, abates glomerular
hyperfiltration. The present study was designed to test the hypothesis that this decrease in
hyperfiltration is specific to acetazolamide and not due to a non specific diuretic effect.
The aim of the present study is to evaluate the effects of the administration of furosemide
p.o. to subjects with severe obesity on glomerular hemodynamics.
Methods: Ten obese subjects will participate in the study. They will undergo measurement of
glomerular filtration rate (inulin clearance) (GFR), renal plasma flow (RPF)
(p-aminohippuric acid clearance), filtration fraction, fractional excretion of lithium (FE
LI) and blood pressure, before and after administration of oral furosemide 20 to 40 mg bid
for 3 days. The effects of furosemide on glomerular hemodynamics in obese subjects will be
compared to the previously studied effects of acetazolamide.
Description:
Almost half of the causes of death in the industrial world are due to cardio-vascular
disease. Two of the main risk factors for CV disease have become much more prevalent during
the last decades, reaching epidemic dimensions in the 21st century: hypertension and
obesity. In 2003-2004, 66% of the adult US population had a BMI over 25, while 32% had a BMI
over 30 .Hypertension is more prevalent in obese than in lean subjects .The cause and effect
relationship between these two conditions is supported by the fact that weight loss is
associated with a decrease in blood pressure .
Salt retention by the kidney is one of the important mechanisms involved in the pathogenesis
of hypertension in obesity. Studies in animal models and in humans showed that increased
salt reabsorption occurs in the tubules in obesity . Another renal functional abnormality
occurring in obesity is glomerular hyperfiltration, characterized by increased RPF and
increased GFR up to twice the normal level . The structural basis to these functional
abnormalities is renal hypertrophy and glomerular enlargement.
These functional and structural abnormalities have deleterious consequences:
1. Increased urinary albumin excretion. Microalbuminuria, an important risk factor for CV
disease, has a high prevalence in obese subjects .
2. Increased risk for the development of focal segmental glomerulosclerosis, the so-called
obesity related glomerulopathy. The incidence of this disease has multiplied 10 times
within 15 yrs in the USA .
3. Increased rate of progression of chronic renal insufficiency in kidney disease not
primarily caused by obesity. Following initial glomerular damage from any cause, the
number of remnant functioning glomeruli decreases. The consequent compensatory increase
in single nephron filtration rate of these remnant glomeruli leads to further
glomerular damage in kidney disease not related to obesity . In the obese with chronic
renal damage, the obesity related hyperfiltration amplifies the compensatory
augmentation in single nephron GFR of remnant nephrons, thus worsening glomerular
damage, irrespective of the cause of the primary insult.
The clinical relevance of these abnormalities is reflected in the sharp increase in the risk
of developing end stage renal disease in the obese. This relative risk, independently of
confounders as diabetes mellitus, hypertension and dyslipidemia, is 3 to 5 depending on the
severity of obesity .
Considering the role of hyperfiltration in the pathogenesis of CKD in the obese, attenuation
of hyperfiltration by pharmacological means may slow down the development and progression of
chronic renal failure. One of the tools available is activating TGF. Tubuloglomerular
feedback (TGF) refers to the alterations in GFR that can be induced by changes in tubular
flow rate. An increase in the delivery of chloride to the macula densa results in a
reduction in GFR, resulting in a decrease in the tubular flow rate delivered to the macula
densa . An increase in chloride delivery to the macula densa can be obtained by
administrating acetazolamide, a diuretic acting on the proximal tubule. We have previously
shown that administration of acetazolamide to obese subjects results in attenuation of
glomerular hyperfiltration.
The aim of the present study is to show that the effect of acetazolamide on GFR is specific
and not due to its diuretic effect. We will study the effects of furosemide, a diuretic
which does not activate TGF ,on GFR and RPF in obese subjects.
METHODS
Inclusion criteria:
10 obese men (BMI>30), aged 18 to 55, with glomerular hyperfiltration (creatinine
clearance>130 ml/min) will be included in the study.
Exclusion criteria:
Any of the following conditions:
- Heart failure
- Known allergy to furosemide, inulin or amino-hippurate
- Pharmacologic treatment for hypertension, cardiac disease, diabetes mellitus
- Treatment with corticosteroids or NSAID
Methods:
A 24-hour urine collection will be performed during the week prior to the renal function
test studies for assessment of sodium intake. Subjects will receive 300 mg of lithium
carbonate at 22.00 the day before the renal function tests. They will be instructed to drink
250 ml of water at bedtime. Renal function tests will start at 08.00 a.m. after a 10-hour
fast, excepting a drink of 250 ml of water at 07.00 a.m. Intravenous catheters will be
placed in each upper limb for infusion of clearance markers and blood sampling. After blood
sampling for urea, creatinine, proteins, glucose, electrolytes, blood gases, insulin, renin,
aldosterone, Hba1c, CBC. A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8
mg/kg) will be administered. Thereafter, inulin and p-aminohippuric acid will be infused
continuously. A 200-300 ml water load will be given during the first 60-min prime. Four
accurately timed urine collections of 40-60 minutes will then be obtained by spontaneous
voiding. Peripheral venous blood will be drawn to bracket each urine collection. Arterial
pressure will be measured by a trained observer, after 30 minutes of rest in the supine
position, using an electronic oscillometric blood pressure measuring device (Datascope,
Accutorr). The cuff will be appropriately sized to the diameter of the arm and the arm
positioned at the heart level. At least 4 measurements will be performed during the study,
each measurement being the mean of 3 readings.
Subjects will be started on furosemide 20 mg every 12 hours, starting on day 1 at 15.00
after the renal function studies. Nine doses will be taken, the last dose on day 4 at 7 am.
In case the blood pressure does not decrease following 20 mg bid furosemide administration,
the study will be repeated after 4 weeks using a dose of 40 mg bid.
Laboratory procedures: Plasma and urinary concentrations of inulin and p-aminohippuric acid
will be analyzed by colorimetric methods (22,23). Lithium in serum and urine will be
measured using the ICP-OES (Inductively Coupled Plasma Optical Emission Spectrometer)
method. Urine microalbumin will be determined by competitive chemiluminescent enzyme
immunoassay (Imulite, DPC, Los Angeles, CA, USA).
Calculations: GFR will be determined from the average value for the timed inulin clearances,
and renal plasma flow (RPF) - from the average value for the timed p-aminohippurate
clearances. The fractional excretion of lithium (FE Li) will be calculated as lithium
clearance / GFR, using two timed urine collections. FE Li will be determined as the average
value for these two measurements Statistical Analysis: The significance of differences
between groups will be evaluated by paired and unpaired two-tailed Student's t-test. The
Student's t-test will be applied to non-normally distributed data (albumin excretion rate
and fractional lithium excretion) after log transformation. P<0.05 will be considered as
significant. The response to treatment with furosemide will be compared to the previously
studied response to treatment with acetazolamide.
